SEC Company Response from Lineage Cell Therapeutics, (LCTX) — Mar 19, 2026
Lineage Cell Therapeutics, Inc.
Date: March 19, 2026 · CIK: 0000876343 · Accession: 0001193125-26-116059
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294202
Letter
Lineage Cell Therapeutics, Inc. 2173 Salk Avenue, Suite 200 Carlsbad, CA 92008 March 19, 2026 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Lineage Cell Therapeutics, Inc. Registration Statement on Form S-3 Filed March 11, 2026 File No. 333-294202 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Lineage Cell Therapeutics, Inc. (the “Company”), hereby respectfully requests that the effectiveness of the registration statement referred to above (the “Registration Statement”) be accelerated so that it becomes effective at 4:30 p.m., Eastern Time, on March 23, 2026, or as soon thereafter as possible. The Company hereby authorizes Edwin Astudillo of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, to orally modify or withdraw this request for acceleration. Please contact me at (442) 287-8967or Mr. Astudillo at (858) 720-8953 when the Registration Statement has been declared effective pursuant to this request and/or with any questions. Sincerely,
Lineage Cell Therapeutics, Inc.
By: /s/ George A. Samuel III
Name: George A. Samuel III
Title: General Counsel and Corporate Secretary
Show Raw Text
CORRESP 1 filename1.htm CORRESP Lineage Cell Therapeutics, Inc. 2173 Salk Avenue, Suite 200 Carlsbad, CA 92008 March 19, 2026 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Lineage Cell Therapeutics, Inc. Registration Statement on Form S-3 Filed March 11, 2026 File No. 333-294202 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Lineage Cell Therapeutics, Inc. (the “Company”), hereby respectfully requests that the effectiveness of the registration statement referred to above (the “Registration Statement”) be accelerated so that it becomes effective at 4:30 p.m., Eastern Time, on March 23, 2026, or as soon thereafter as possible. The Company hereby authorizes Edwin Astudillo of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, to orally modify or withdraw this request for acceleration. Please contact me at (442) 287-8967or Mr. Astudillo at (858) 720-8953 when the Registration Statement has been declared effective pursuant to this request and/or with any questions. Sincerely, Lineage Cell Therapeutics, Inc. By: /s/ George A. Samuel III Name: George A. Samuel III Title: General Counsel and Corporate Secretary